- patients with uncontrolled systemic fungal and bacterial infections - patients with latent tuberculosis - patients with known hypersensitivity to tocilizumab or any component of the formulation - concurrent initiation of steroid therapy is not allowed - patients with uncrontroled malignant disease, with a life expectancy of 3 months or less

- patients with uncontrolled systemic fungal and bacterial infections - patients with latent tuberculosis - patients with known hypersensitivity to tocilizumab or any component of the formulation - concurrent initiation of steroid therapy is not allowed - patients with uncrontroled malignant disease, with a life expectancy of 3 months or less